QIAGEN Gross Margin 2010-2023 | QGEN
Current and historical gross margin for QIAGEN (QGEN) over the last 10 years. The current gross profit margin for QIAGEN as of March 31, 2023 is %.
| QIAGEN Gross Margin Historical Data |
| Date |
TTM Revenue |
TTM Gross Profit |
Gross Margin |
| 2023-03-31 |
$2.00B |
$1.28B |
63.88% |
| 2022-12-31 |
$2.14B |
$1.39B |
64.66% |
| 2022-09-30 |
$2.23B |
$1.44B |
64.73% |
| 2022-06-30 |
$2.26B |
$1.46B |
64.44% |
| 2022-03-31 |
$2.31B |
$1.50B |
64.66% |
| 2021-12-31 |
$2.25B |
$1.45B |
64.46% |
| 2021-09-30 |
$2.24B |
$1.45B |
64.73% |
| 2021-06-30 |
$2.19B |
$1.43B |
65.51% |
| 2021-03-31 |
$2.07B |
$1.36B |
65.86% |
| 2020-12-31 |
$1.87B |
$1.23B |
65.94% |
| 2020-09-30 |
$1.71B |
$1.14B |
66.59% |
| 2020-06-30 |
$1.61B |
$1.07B |
66.67% |
| 2020-03-31 |
$1.55B |
$1.03B |
66.13% |
| 2019-12-31 |
$1.53B |
$1.01B |
65.88% |
| 2019-09-30 |
$1.52B |
$0.99B |
65.33% |
| 2019-06-30 |
$1.51B |
$0.99B |
65.67% |
| 2019-03-31 |
$1.51B |
$1.00B |
66.42% |
| 2018-12-31 |
$1.50B |
$1.00B |
66.71% |
| 2018-09-30 |
$1.50B |
$1.00B |
66.71% |
| 2018-06-30 |
$1.48B |
$0.98B |
66.26% |
| 2018-03-31 |
$1.45B |
$0.95B |
65.54% |
| 2017-12-31 |
$1.42B |
$0.92B |
65.09% |
| 2017-09-30 |
$1.39B |
$0.89B |
64.12% |
| 2017-06-30 |
$1.36B |
$0.87B |
63.83% |
| 2017-03-31 |
$1.35B |
$0.86B |
63.50% |
| 2016-12-31 |
$1.34B |
$0.85B |
63.15% |
| 2016-09-30 |
$1.32B |
$0.84B |
63.71% |
| 2016-06-30 |
$1.30B |
$0.83B |
63.66% |
| 2016-03-31 |
$1.28B |
$0.82B |
63.62% |
| 2015-12-31 |
$1.28B |
$0.83B |
64.64% |
| 2015-09-30 |
$1.29B |
$0.82B |
63.47% |
| 2015-06-30 |
$1.31B |
$0.84B |
63.82% |
| 2015-03-31 |
$1.33B |
$0.85B |
64.38% |
| 2014-12-31 |
$1.34B |
$0.87B |
64.36% |
| 2014-09-30 |
$1.35B |
$0.89B |
65.80% |
| 2014-06-30 |
$1.33B |
$0.87B |
65.59% |
| 2014-03-31 |
$1.32B |
$0.83B |
62.81% |
| 2013-12-31 |
$1.30B |
$0.82B |
62.67% |
| 2013-09-30 |
$1.29B |
$0.81B |
63.12% |
| 2013-06-30 |
$1.27B |
$0.80B |
63.07% |
| 2013-03-31 |
$1.26B |
$0.84B |
66.16% |
| 2012-12-31 |
$1.25B |
$0.82B |
65.71% |
| 2012-09-30 |
$1.24B |
$0.79B |
63.90% |
| 2012-06-30 |
$1.23B |
$0.78B |
63.78% |
| 2012-03-31 |
$1.20B |
$0.77B |
63.86% |
| 2011-12-31 |
$1.17B |
$0.75B |
64.16% |
| 2011-09-30 |
$1.12B |
$0.74B |
65.74% |
| 2011-06-30 |
$1.11B |
$0.73B |
66.00% |
| 2011-03-31 |
$1.09B |
$0.72B |
65.78% |
| 2010-12-31 |
$1.09B |
$0.72B |
65.87% |
| 2010-09-30 |
$1.09B |
$0.72B |
65.60% |
| 2010-06-30 |
$1.08B |
$0.71B |
65.71% |
| 2010-03-31 |
$1.05B |
$0.69B |
65.91% |
| 2009-12-31 |
$1.01B |
$0.67B |
66.04% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$10.347B |
$2.142B |
|
QIAGEN N.V. is one of the world's leading providers of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA. The company provides innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions. It has developed a comprehensive portfolio of proprietary, consumable products, and automated solutions for sample collection. Qiagen has subsidiaries several other countries with good sales potential. Segment Details Consumables: These are typically sample preparation or test kits that contain all the necessary reagents and buffers, and a manual including protocols and relevant background information. Automated Instruments: These automate the use of Sample & Assay Technologies into efficient solutions for a broad range of laboratory needs. Customer Classes: QIAGEN focuses on 4 principal segments or customer classes for sample and assay technologies:? Molecular Diagnostics, Applied Testing, Pharma and Academia.
|
